Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.

Webb DL, Rudholm-Feldreich T, Gillberg L, Halim MA, Theodorsson E, Sanger GJ, Campbell CA, Boyce M, Näslund E, Hellström PM.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Jan;386(1):41-9. doi: 10.1007/s00210-012-0812-5. Epub 2012 Nov 24.

PMID:
23179899
2.

YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.

Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, Takemoto Y, Ohta M, Satoh M, Semple G, Miyata K.

Aliment Pharmacol Ther. 1997 Feb;11(1):113-20.

3.

Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.

Kitano M, Norlén P, Ding XQ, Nakamura S, Håkanson R.

Br J Pharmacol. 2000 Jun;130(3):699-705.

4.

Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula.

Takemoto Y, Yuki H, Nishida A, Ito H, Kobayashi-Uchida A, Takinami Y, Akuzawa S, Ohta M, Satoh M, Semple G, Miyata K.

Arzneimittelforschung. 1998 Apr;48(4):403-7.

PMID:
9608884
5.

A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation.

Kidd M, Modlin IM, Black JW, Boyce M, Culler M.

Regul Pept. 2007 Oct 4;143(1-3):109-17. Epub 2007 Apr 29.

PMID:
17531331
6.

The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.

Sørdal Ø, Waldum H, Nordrum IS, Boyce M, Bergh K, Munkvold B, Qvigstad G.

Helicobacter. 2013 Dec;18(6):397-405. doi: 10.1111/hel.12066. Epub 2013 Jul 19.

PMID:
23865485
7.

Bravo capsule system optimizes intragastric pH monitoring over prolonged time: effects of ghrelin on gastric acid and hormone secretion in the rat.

Rudholm T, Hellstrom PM, Theodorsson E, Campbell CA, McLean PG, Naslund E.

World J Gastroenterol. 2008 Oct 28;14(40):6180-7.

8.

Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.

Takaishi S, Cui G, Frederick DM, Carlson JE, Houghton J, Varro A, Dockray GJ, Ge Z, Whary MT, Rogers AB, Fox JG, Wang TC.

Gastroenterology. 2005 Jun;128(7):1965-83.

PMID:
15940630
9.
10.

The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.

Kidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, Black JW, Boyce M, Modlin IM.

Regul Pept. 2010 Jun 8;162(1-3):52-60. doi: 10.1016/j.regpep.2010.01.009. Epub 2010 Feb 6.

PMID:
20144901
11.

Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms.

Fornai M, Colucci R, Antonioli L, Awwad O, Ugolini C, Tuccori M, Fulceri F, Natale G, Basolo F, Blandizzi C.

Pharmacol Res. 2011 Jan;63(1):59-67. doi: 10.1016/j.phrs.2010.10.013. Epub 2010 Oct 20.

PMID:
20969958
12.

Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.

Makovec F, Revel L, Letari O, Mennuni L, Impicciatore M.

Eur J Pharmacol. 1999 Mar 12;369(1):81-90.

PMID:
10204685
13.

Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.

Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM.

PLoS One. 2013 Oct 1;8(10):e76462. doi: 10.1371/journal.pone.0076462. eCollection 2013.

14.

Acceleration of ulcer healing by cholecystokinin (CCK): role of CCK-A receptors, somatostatin, nitric oxide and sensory nerves.

Brzozowski T, Konturek PC, Konturek SJ, Pajdo R, Drozdowicz D, Kwiecień S, Hahn EG.

Regul Pept. 1999 Jun 30;82(1-3):19-33.

PMID:
10458643
15.
16.

(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.

Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S, Miyata K.

J Med Chem. 1997 Jan 31;40(3):331-41.

PMID:
9022799
18.

Role of gastrin in the development of gastric mucosa, ECL cells and A-like cells in newborn and young rats.

Björkqvist M, Dornonville de la Cour C, Zhao CM, Gagnemo-Persson R, Håkanson R, Norlén P.

Regul Pept. 2002 Oct 15;108(2-3):73-82.

PMID:
12220729
19.
20.

CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs.

Evilevitch L, Weström BR, Pierzynowski SG.

Scand J Gastroenterol. 2004 Sep;39(9):886-90.

PMID:
15513388
Items per page

Supplemental Content

Write to the Help Desk